Atherosclerosis:中国成人血脂异常知晓率、治疗率和控制率非常低

2016-04-02 徐媛 MedSci原创

本研究分析了中国成人血脂异常患病率。在这项横断面研究中,研究人员采用多阶段分层抽样方法从来自中国不同的城市和农村地区大于18岁的成人中获得代表性样本。对所有受试者进行了生活方式和病史问卷调查。血脂异常知晓率定义为患者自我报告知道患有血脂异常。 研究人员收纳了来自2007年-2010年43368名成人的血脂数据,血脂异常的患病率是34.0%,其中城镇居民和农村居民血脂异常患病率分别为35.1%和2

本研究分析了中国成人血脂异常患病率。在这项横断面研究中,研究人员采用多阶段分层抽样方法从来自中国不同的城市和农村地区大于18岁的成人中获得代表性样本。对所有受试者进行了生活方式和病史问卷调查。血脂异常知晓率定义为患者自我报告知道患有血脂异常。

研究人员收纳了来自2007年-2010年43368名成人的血脂数据,血脂异常的患病率是34.0%,其中城镇居民和农村居民血脂异常患病率分别为35.1%和26.3%。男性血脂异常的患病率明显高于女性(41.9%比32.5%,P < 0.001)。在人群中,认识到自己血脂异常、接受治疗的和得到控制的患者分别为31.0%,19.5%,和8.9%。

多元回归分析得到,年龄增加(OR = 1.012; 95% CI, 1.01.-1.014)、男性(OR = 1.411; 95% CI, 1.318-1.510)、肥胖(OR = 1.424; 95% CI, 1.345-1.507)、心血管疾病(OR = 1.343; 95% CI, 1.125-1.603)、糖尿病(OR = 1.955; 95% CI, 1.751-2.182)、高血压(OR = 1.481; 95% CI, 1.391-1.577)和高尿酸血症(OR = 2.223; 95% CI, 2.060-2.399)是血脂异常的独立危险因素。

研究结果显示,中国成人血脂异常的患病率高,知晓率、治疗率和控制率非常低。与农村居民相比,城镇居民有更高的患病率,而且要进一步密切监控和控制高危因素人群包括绝经后妇女,不健康生活方式的民族和慢性非传染性疾病患者。

原始出处

Pan L1, Yang Z1, Wu Y1, Yin RX2, Liao Y3, Wang J4, Gao B4, Zhang L4; China National Survey of Chronic Kidney Disease Working Group.The prevalence, awareness, treatment and control of dyslipidemia among adults in China.Atherosclerosis. 2016 Feb 27

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
    2016-04-04 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
    2016-04-03 chenchuny

    这是早就定论了的

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
    2016-04-03 chenchuny

    这是早就定论了的

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
    2016-04-03 chenchuny

    这是早就定论了的

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
    2016-04-02 cjingjuan

    需要重视阿

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
    2016-04-02 Gsurgeon

    评论系统出问题啦?

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1693397, encodeId=7da4169339ee3, content=<a href='/topic/show?id=93abe31513d' target=_blank style='color:#2F92EE;'>#知晓率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73151, encryptionId=93abe31513d, topicName=知晓率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fd929423073, createdName=xuqianhua, createdTime=Sat Dec 03 18:31:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947310, encodeId=6b80194e310d2, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Jul 19 01:31:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253715, encodeId=5aac1253e15bd, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364103, encodeId=78591364103e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 04 12:31:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75321, encodeId=b7f9e532192, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75322, encodeId=b63ee53225f, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75323, encodeId=cccee5323a2, content=这是早就定论了的, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Sun Apr 03 07:49:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75295, encodeId=e1cae5295f9, content=需要重视阿, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Apr 02 23:18:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75279, encodeId=3828e527929, content=评论系统出问题啦?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:12:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75278, encodeId=4c3de527899, content=是的我们重视不够, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Apr 02 22:09:00 CST 2016, time=2016-04-02, status=1, ipAttribution=)]
    2016-04-02 Gsurgeon

    是的我们重视不够

    0

相关资讯

Circulation: 应用他汀药物后,血脂和冠心病发生风险之间的相关性减弱

背景:2001年胆固醇治疗指南发表后,US冠心病成人中他汀类药物的应用增加。方法:研究者收集REGARDS研究中的9578名受试者及KPSC中346 595人,2003年到2007年间的血脂水平,评估血脂和CHD之间的相关性。研究者也收集了1987到1989 ARIC研究中14 590名受试者的血脂水平,对其进行相同的分析。分析限制在45到64岁间,没有CHD,也没有服用他汀类药物的黑人和白人。基

混合型血脂异常,治疗有何特殊性?

混合型血脂异常是以甘油三酯(TG)和胆固醇升高,高密度脂蛋白胆固醇(HDL-C)降低为特点的一种血脂异常类型。目前认为除HDL-C以外的其他脂蛋白,均可列入致动脉粥样硬化血脂谱,是动脉粥样硬化性心血管疾病的独立危险因素。兼顾多种脂质成分的联合治疗对心血管疾病防治具有重要意义。 一、高TG与心血管疾病的关系 他汀类药物可降低LDL-C水平,从而减少动脉粥样硬化事件,这已被众多大型临床研究所证

郭艺芳:解读2016年ADA糖尿病管理标准

【糖尿病患者降压治疗的解读】 2016年美国糖尿病协会(ADA)管理标准颁布后,在国内引起广泛关注。与2015年指南相比,新指南进行了多项更新。关于降压治疗的要点及其解析如下: 1.糖尿病患者每次就诊时均应检测血压。 【解析】 高血压与糖尿病均为心血管系统的最重要危险因素,二者同时存在时患者心血管风险水平显著增高。约60%左右的糖尿病患者并存高血压,因此

JAMA:想降低血脂?或许医患双方都需要来点金钱刺激

该研究的目的是探究相比控制手段,医生金融激励措施、医生和患者金融激励措施或共享激励措施对心血管疾病高风险民众降低低密度脂蛋白胆固醇(LDL-C)水平是否更有效果。

降脂新药Evolocumab并不会带来更多益处

降脂新药PCSK9抑制剂Evolocumab(Repatha)于2015年7月上市,用于高胆固醇血症或混合型血脂异常、纯合子家族性高胆固醇血症的治疗。饮食和其他药物不能好好控制血脂的患者可以选择该药物。IQWiG检查了相关档案评估evolocumab是否会比适当的治疗益处更多。因为缺乏足够的数据,因此对这两种适应症均没有发现更大的益处。血液中LDL胆固醇水平过高会被诊断为高胆固醇血症,混合型血脂异

Clin Lab:卒中类型不同,血脂代谢不同

背景:越来越多的流行病学研究已经确定了血脂异常与动脉粥样硬化性卒中之间的关系密切。的确,脂类代谢在不同的卒中类型中存在差异。有关特定类型的缺血性卒中的危险因素的研究较少,尤其是,有关血脂异常的作用的证据较少。本研究旨在确定急性缺血性卒中类型和血脂水平的关系。方法:检测362例缺血性脑卒中患者和181例健康对照者血脂,包括TC、TG、LDL-C、HDL-C、ApoA、ApoB、ApoE水平和LP(a